Pipeline

We are advancing a diverse portfolio of novel therapies across our  campaign areas of Metabolic disease. 

PRM A Hypoglycemia

Diabetes and Obesity

Nash

 

  • Hypoglycemia affects over 100 million people. It is prevalent in 90% of T1D patients and 25% of T2DM patients. Severe hypoglycemia can lead to death. 

  • There is no preventative treatment. 

  • Pramana’s Lead Compound, PRM A has shown significant and differentiating glucagon response. PRM A acts as a smart modulator for glycemic control and is expected to be a once a day oral.

  • PRM A is positioned to be a prevention for hypoglycemia.

One person dies from diabetes and its complications every eight seconds and obesity is a cause for nearly 1 out of 5 adult deaths Over 40% of the U.S. population is living with obesity and minority group members are disproportionally impacted In the US, fewer than 3% of people with obesity are pharmacologically treated for obesity. The economic impact  associated with obesity is over $1 trillion dollars.

 

Our R&D focus for liver and metabolic disease is NASH. Among the largest unmet medical needs globally, NASH and metabolic diseases represent a leading cause of morbidity and mortality and a significant burden for patients and healthcare systems.

  • 19.3M

PATIENTS IN U.S WITH NASH IN 2020
 
  • 27M

PATIENTS IN U.S. PROJECTED WITH NASH BY 2030
 
  • 8.3M

PATIENTS IN U.S. WITH NASH WITH F2, F3 OR F4 FIBROSIS IN 2020
 
  • $100B

ANNUAL ECONOMIC BURDEN OF NAFLD AND NASH IN US IN 2016

Our molecular library has the potential to address this area of high unmet need and
generate potential candidates through screening and development Our compounds have multiple pathways of interest which could assist in the regulation of cardio-metabolic processes and liver function.